Brain Tumors, Metastatic Cancer, and Paraneoplastic Syndromes

Chapter 19 Brain Tumors, Metastatic Cancer, and Paraneoplastic Syndromes


With their unpredictable onset and frequently tragic course, brain tumors command unique attention. Moreover, they seem to arise in children and adults in the prime of their life. Because brain tumors may produce depression, thought disorders, or cognitive impairment without any accompanying physical symptoms, they occasionally mimic psychiatric disturbances. Brain tumors remain the bête noire of psychiatry.



Varieties



Primary Brain Tumors


Primary brain tumors arise within the brain or spinal cord tissue (parenchyma) or their coverings (meninges) (Box 19-1). Pathologists have named them after their original cell line. The numerous, mostly small, glial cells, which normally provide the structural, biochemical, and immunologic support for the central nervous system (CNS), give rise to most tumors – gliomas. These tumors arise within the substance of the brain, i.e., in intraparenchymal or intra-axial locations. Meningeal cells give rise to the other large category of brain tumors, meningiomas. Because these tumors arise from the coverings of the CNS, rather than from actual brain or spinal cord tissue, they grow outside the brain, i.e., in extraparenchymal (extra-axial) locations. In contrast, CNS neurons rarely form tumors in adults.



Of the various potential etiologies of primary brain tumors, studies have established that only ionizing radiation, certain neurocutaneous disorders (see Chapter 13), and various genetic mutations constitute risk factors. So far, data have not proven that cellphone use constitutes a risk factor.



Gliomas


Parenchymal tumors, gliomas, include oligodendrogliomas and astrocytomas. Oligodendrocytes, which normally produce the myelin covering that insulates CNS neurons,* may give rise to oligodendrogliomas. These tumors, which occur infrequently and grow slowly, produce similar manifestations to the more commonly occurring astrocytomas (see later).


Astrocytomas, which arise from astrocytes, strike children as well as adults. They do not invade surrounding tissue when they are low-grade, but originate anywhere in the CNS. They are the most common tumor in children. In children, relatively benign astrocytomas grow into cystic, noninvasive tumors in the cerebellum. Because neurosurgeons can readily remove an entire cerebellar astrocytoma without causing appreciable sequelae, the cure rate approaches 90% of this variety of tumor in children. However, in children, astrocytomas may arise in the brainstem, where they invade cranial nerve nuclei and long tracks. Brainstem astrocytomas tend to be highly malignant and not amenable to surgery.


For adults, astrocytomas occur predominantly in the cerebrum, infiltrate extensively, and often degenerate into glioblastomas. Total surgical removal is practical only when the surrounding brain can be sacrificed. For low-grade astrocytomas, combined surgery and radiotherapy prolong life for approximately 10 years.


Glioblastomas, the most malignant variety of astrocytoma, are the most frequently occurring brain tumor. They develop almost exclusively in the cerebrum. The prognosis is grim. These tumors not only grow rapidly and relentlessly, they infiltrate widely. Frontal lobe gliomas frequently cross the corpus callosum to produce the infamous “butterfly glioma” (Figs 19-1, A, 20-8, and 20-20). Contrary to many physicians’ expectations that brain tumors, like most other cancers, arise in the elderly, the age of patients at the time of a glioblastoma diagnosis averages only 54 years.


image

FIGURE 19-1 A, A glioblastoma – the most malignant form of glioma – typically infiltrates along white-matter tracts. Sometimes it spreads through the heavily myelinated corpus callosum in a “butterfly” pattern (see Figs 20-8 and 20-20). B, Meningiomas arise from the meninges overlying the brain or spinal cord and grow slowly (see Fig. 20-10). They compress and irritate, but do not infiltrate, the central nervous system. C, Metastatic tumors, usually multiple and surrounded by edema, destroy large areas of brain and raise intracranial pressure (see Fig. 20-8). D, A subdural hematoma, typically located over one cerebral hemisphere (see Fig. 20-9), compresses the underlying brain and ventricles, and pushes away (shifts) midline structures. Large, acute, rapidly expanding subdural hematomas force the brainstem and ipsilateral oculomotor (third cranial) nerve through the tentorial notch. Such transtentorial herniation, which occurs with epidural as well as subdural hematomas (see Chapter 22), constitutes an immediately life-threatening condition. In contrast, small meningiomas and chronic subdural hematomas cause relatively few symptoms because they are extra-axial and exert little mass effect.


Radiotherapy, steroids, and chemotherapy may slow glioblastomas’ growth rate and provide a brief, physically comfortable period. Surgical excision rarely eliminates these tumors. In fact, many patients, especially the elderly and those with pronounced neurologic deficits, gain little from treatment. Glioblastoma patients survive for only about 15 months. Moreover, persistence of the tumor and side effects of treatment often produce progressive cognitive and emotional deterioration.





Metastatic Tumors


Systemic tumors metastasize to the brain and spinal cord by hematogenous routes. They cannot spread through a lymphatic system because the brain, unlike almost all other organs, does not have one. Metastatic tumors tend to be multiple, surrounded by edema, and rapidly growing. Although individual tumors may each be small, their combined mass constitutes an oppressive intracerebral burden (see Figs 19-1, C and 20-8).


Cancer of the lung, breast, kidney, and skin (malignant melanomas) most often give rise to cerebral metastases. In contrast, because the portal vein diverts metastases to the liver, gastrointestinal, pelvic, and prostatic cancers spread to the brain rarely or only late in their course.


Approximately 15% of all cancer patients initially have symptoms of cerebral metastases; however, as treatment drives systemic tumors into long remissions, cerebral metastases, which usually do not respond to therapy, cause symptoms in a greater proportion of patients. Metastases resist systemic chemotherapy because the blood–brain barrier ironically blocks most medications from attacking them. Moreover, chemotherapy and radiotherapy have relatively little effect against metastatic tumors because, compared to the primary tumor, they are poorly differentiated. On the other hand, the discovery of a metastatic brain tumor is occasionally the first indication that a person has cancer.


Whatever the origin of cerebral metastases, conventional treatments, such as steroids and radiotherapy, provide palliative care. Stereotactic radiosurgery, which consists of a cobalt device, linear accelerator, or a cyclotron delivering a highly focused beam of radiation to metastases, alone or in conjunction with whole-brain radiation, usually shrinks the tumors. In cases involving a single metastasis, surgeons can help the patient, at least temporarily, by removing it. Nevertheless, most patients with metastatic brain tumors survive less than 9 months.



Initial Symptoms



Local Signs


By damaging surrounding tissue, brain tumors usually produce lateralized neurologic deficits, often called “local signs,” such as hemiparesis and dominant- or nondominant-hemisphere neuropsychologic disorders (see Chapter 8). Tumors arising in “eloquent” regions – cerebral cortex areas critical to motor or neuropsychologic function, such as Broca’s or Wernicke’s areas – produce obvious impairments. Tumors that are small, slowly growing, or located in “silent” regions of the brain, such as the right frontal lobe or either of the anterior temporal lobes, notoriously fail to produce symptoms. Tumors that arise from cranial nerves, although rare, almost immediately result in readily recognizable deficits. For example, optic nerve gliomas cause visual loss, and acoustic neuromas cause unilateral progressive hearing loss and tinnitus (see later).


Seizures in individuals older than 60 years are frequently the presenting feature of cerebral tumors. However, because strokes cause seizures nearly as often as tumors, a 60-year-old individual presenting with the first seizure is approximately equally likely to have sustained a stroke as have developed a brain tumor. When the etiology is either a brain tumor or stroke, seizures typically begin as a partial seizure that undergoes secondary generalization (see Chapter 10).


A brain tumor’s tendency to cause seizures also pertains to electroconvulsive therapy (ECT). For example, if a patient harboring a brain tumor were to undergo ECT, the procedure might give rise to multiple, uninterrupted, life-threatening seizures (status epilepticus). However, the benefits of ECT might outweigh the risks if the tumor were small enough not to cause neurologic deficits or surrounding cerebral edema. Large brain tumors, on the other hand, constitute an unequivocal problem regarding ECT. Not only might large brain tumors account for depressive symptoms, but also they might precipitate transtentorial herniation during ECT (Fig. 19-1, D). Thus, before their patients undergo ECT, neurologists order either an MRI or CT.



Signs of Increased Intracranial Pressure


In addition to damaging brain tissue, tumors may raise intracranial pressure through many mechanisms. They grow rapidly, constitute a large volume, accumulate surrounding edema, obstruct the flow of cerebrospinal fluid (CSF) through the ventricles, or impede CSF reabsorption through the arachnoid villi. Whatever the cause, increased pressure (pressures exceeding 200 mm H2O) creates symptoms and signs that may add to or supersede local ones.


Headache, while the most common symptom of increased intracranial pressure, still occurs in only one-half of patients. Although brain-tumor-induced headache lacks distinctive features, it usually resembles tension-type headache because it consists of diffuse, dull, relatively mild pain that initially responds to mild analgesics, including aspirin. Sometimes, a predominantly localized or unilateral headache points to a tumor’s location and mimics migraine. In any case, as pressure rises, headaches worsen, especially in the early-morning hours, and begin to awaken patients from sleep. Increasing intracranial pressure eventually produces nausea and vomiting, as well as increasing intense headache.


Despite the statistic that fewer than 1 out of 1000 people with headache harbors a brain tumor, both patient and physician frequently have great concerns – spoken or unspoken – that any headache may indicate a brain tumor. These concerns sometimes thwart diagnosis of a less threatening disorder, such as migraine or depression. Neurologists, dispensing with lengthy explanations or reassurances, often simply order a CT or MRI to exclude a tumor and move on with their evaluation and treatment plan.


Another sign of increased intracranial pressure, papilledema, occurs as pressure is transmitted along the optic nerve to the optic disks (Fig. 19-2). Although papilledema has a notorious association with brain tumors, it occurs late, if at all, in their course. In fact, among young adults, especially overweight females with menstrual irregularity, idiopathic intracranial hypertension (pseudotumor cerebri) is much more likely than a brain tumor to explain papilledema (see Chapter 9). In general, because only a small proportion of brain tumor patients have papilledema during an initial examination, its absence should not be taken as evidence against the presence of a brain tumor.



In considering manifestations of brain tumors, meningiomas constitute a special category. Unlike gliomas, as discussed previously, small meningiomas are common and usually small. Even large ones may remain asymptomatic. Also, they arise and usually remain entirely in extra-axial locations and produce characteristic syndromes. For example, a meningioma arising from the falx, a parasagittal meningioma, can compress the medial motor cortex and cause spastic paresis of one or both legs. A meningioma arising from the sphenoid wing can damage the adjacent temporal lobe and, because of its proximity to the orbit, cause proptosis and paresis of eye movement. Likewise, an olfactory groove meningioma can compress the adjacent olfactory and optic nerves and the overlying frontal lobe (see Foster–Kennedy syndrome, Chapter 4), causing anosmia, unilateral blindness, and, when large, frontal lobe dysfunction (see Chapter 7).



Initial Mental Symptoms



Direct Effects of Tumors


As a preliminary practical point, most rapidly evolving tumor-related cognitive impairments or personality changes result from a glioblastoma. Another point is that tumors in the frontal lobe produce “frontal lobe personality changes,” consisting of psychomotor retardation, emotional dulling, loss of initiative, poor insight, and reduced capacity to execute complex mental tasks. This clinical picture, like the clinical picture of frontotemporal dementia (see Chapter 7), consists of disturbances in behavior and affect that overshadow cognitive impairments, and those disturbances in turn overshadow physical impairments.


In a somewhat opposite effect, frontal lobe tumors sometimes impair normal inhibitory systems. Patients with lack of inhibition (disinhibition) may overreact to an irritation, liberally use profanities, cry with little provocation, jump excitedly from topic to topic, and speak without tolerating interruptions. By way of contrast, parietal or occipital lobe, as well as right-sided far anterior frontal, tumors, unless they cause increased intracranial pressure, have relatively little effect on mood or cognitive function.


Overall, with numerous potential causes, depression is a frequent comorbidity of brain tumor. Depressive symptoms not only arise soon after diagnosis, but they increase in prevalence and severity during the ensuing illness, and predict a poor quality of life.


In brain tumor cases, a psychiatrist might attempt to determine the patient’s mood, cognitive capacity, neurologic deficits, and iatrogenic factors. With no standard guidelines for prescribing antidepressants or other psychotropics, psychiatrists must approach each situation entirely on an individual basis. In addition to prescribing a psychotropic and precluding ECT, psychiatrists might offer advice on alterations in mental status, guide pain management, assist in appointing a health care proxy, and help with decisions about end-of-life care.



Medication and Other Treatment


Opioids can cause delirium and undesirable changes in mood. On the other hand, insufficient opioids can lead to suffering, insomnia, and drug-seeking behavior. Benzodiazepines and hypnotics also present a quandary. They help control pain, anxiety, and insomnia, but may themselves cause mental dullness, confusion, and disruption of the sleep–wake cycle.


Other medications likely to induce mental status changes in cancer patients are antiepileptic drugs (AEDs), steroids, antiemetics, and antihistamines. Although physicians can usually predict common medications’ potential physical side effects, their mental side effects in cancer patients often arise insidiously and unexpectedly. For example, patients might have undiagnosed liver metastases that slow metabolism of medications and allow their unexpected accumulation. Similarly, because cancer patients often have lost body mass, physicians may inadvertently prescribe relatively large doses of a medicine. When cancer involves several organs, various specialists may each order different medicines that not only cause mental status abnormalities, but also may adversely interact.


Chemotherapy agents generally do not cause mental status changes because they cannot penetrate the blood–brain barrier. An exception occurs when physicians administer methotrexate intrathecally (into the subarachnoid space, usually through a lumbar puncture [LP]) because it often causes adverse CNS effects. Although intrathecal methotrexate, which is frequently administered in conjunction with cranial radiotherapy, may protect children from leukemic cells invading the CNS, it often induces short-term confusional states and occasional permanent learning disabilities and personality changes.


Many times chemotherapy penetrates the barrier and damages oligodendrocytes, which are the most vulnerable CNS cells. After 3 months to 5 years after treatment, loss of the oligodendrocytes leads to demyelination. Cancer survivors who sustain chemotherapy-induced CNS demyelination typically have cognitive decline and personality changes, paresis and spasticity, and ataxia and gait impairment – alone or in combination. Their MRIs show demyelination.


In contrast to chemotherapy-induced CNS demyelination, chemotherapy-induced peripheral neuropathy, from damage of either axons or the myelin-generating Schwann cells, usually occurs during or shortly after chemotherapy. Although severe enough at times to cause paresis and painful sensory impairment, chemotherapy-induced neuropathy tends to improve.


In an acute, often debilitating side effect, chemotherapy tends to induce nausea and vomiting (chemotherapy-induced emesis). This problem usually stems from chemotherapy agents triggering the brain’s chemoreceptor zone and its adjacent vomiting center. These zones are located in the area postrema of the medulla, which is one of the few regions of the brain unprotected by the blood–brain barrier. The absence of a blood–brain barrier leaves the chemoreceptor zone freely accessible to any blood-borne substance. Thus, if people inadvertently ingest toxins, such as in poisonous mushrooms, they will immediately vomit. From a medical perspective, morphine, heroin, and high doses of L-dopa, as well as several chemotherapeutic agents, activate the chemoreceptor zone and induce vomiting. On the other hand, both dopamine-blocking agents and 5-HT3 antagonists prevent chemotherapy-induced nausea and vomiting (see Chapter 21).


Depending on the radiation’s total dose and rapidity with which it is administered, radiotherapy sometimes causes inflammatory arteritis and necrosis. Small strokes, which begin to accumulate 6–18 months after a course of radiotherapy, lead to a stepwise progression of cognitive impairments and personality changes resembling vascular cognitive impairment (see Chapter 11). Hemiparesis and dysarthria often accompany neuropsychologic changes. MRIs of patients with radiation-induced cognitive impairments typically reveal white-matter changes (leukoencephalopathy). Overall, radiotherapy induces more cognitive impairment than most chemotherapy agents.


Whole-brain radiation administered to children for acute leukemia or brain tumors may result not only in cognitive impairment, but also in problems from hypothalamic–pituitary deficiency, particularly growth retardation, developmental delay, and late, incomplete puberty. Compared to young and middle-aged adults, children are more susceptible to radiation-induced cognitive impairment.


In an analogous complication, radiotherapy of the spine or mediastinum can strike the spinal cord and cause spinal cord radiation necrosis (radiation myelitis). Similarly, radiation of pituitary tumors may lead to necrosis of the adjacent pituitary gland. In this situation, radiation scatter may also cause necrosis of the nearby medial inferior temporal lobes. Young adult survivors of childhood non-CNS cancers, such as Hodgkin disease that required radiation of the chest and neck, also have an increased incidence of stroke. Their strokes occur because the extracranial portions of the carotid and vertebral arteries develop radiation-induced fibrosis that occludes the vessels.



Infections and Organ Failure


Immunosuppressive agents, radiotherapy, and various open ports, such as intravenous lines and urinary catheters, leave cancer patients susceptible to systemic infection. Bacteria, fungi, and opportunistic organisms frequently invade and proliferate, without provoking an immunologic response, and cause sepsis.


In addition, systemic cancer, infections, and various treatments often cause renal, pulmonary, or hepatic failure. Alone or together, sepsis and organ failure often lead to delirium. Perhaps owing to a comorbid depression, delirium in cancer patients may consist primarily of apathy, reticence, and sleep disturbance.


Infective agents sometimes invade the CNS, but not other organs. Because cancer patients often cannot respond with fever or leukocytosis to an infection, they may not show the usual markers. In fact, only 5% of cancer patients with meningitis will have the classic triad of fever, nuchal rigidity, and encephalopathy. Also, because of their immunocompromised state, cancer patients are susceptible to opportunistic infections. For example, progressive multifocal leukoencephalopathy (PML) probably results from a papovavirus that attacks CNS myelin. Indeed, CSF analysis in PML cases yields JC virus DNA. Usually complicating the late course of an illness, PML causes dementia and variable physical impairments, but not delirium, fever, or leukocytosis. PML has also complicated AIDS and immunosuppression therapy, including the multiple sclerosis treatment natalizumab (see Chapters 7, 15, and 20).




Paraneoplastic Syndromes


Systemic cancer sometimes causes neurologic syndromes not by invading the nervous system, but by inciting antibody-mediated immune responses directed against the CNS, PNS, or neuromuscular junction. Neurologists previously aptly called these disorders “remote effects of carcinoma,” but now they term them paraneoplastic syndromes. Paraneoplastic syndromes seem to begin with the patient’s synthesizing antibodies against a tumor’s antigens. The antibodies cross-react with neurons’ intracellular components, cell surfaces, or synaptic receptors. Antibodies involved in paraneoplastic syndromes include ones directed against voltage-gated potassium channels (VGKC) and N-methyl-D-aspartate (NMDA) receptors. Of the numerous paraneoplastic syndromes, three are particularly relevant: Cerebellar degeneration, limbic encephalitis, and Lambert–Eaton myasthenic syndrome (LEMS). Their pathophysiology likely represents “molecular mimicry” that is analogous to antistreptococcal antibodies cross-reacting with basal ganglia to cause Sydenham chorea (see Chapter 18).


Patients with paraneoplastic syndromes often show symptoms several months before or after the discovery of an underlying tumor. When neurologists diagnose a paraneoplastic syndrome in a patient without a known malignancy, they often order positron emission tomography (PET) and other tests for an occult malignancy. If physicians detect the underlying tumor and patients undergo surgery or chemotherapy that removes or shrinks it, paraneoplastic syndromes usually subside. Alternatively, immunosuppressive treatments, such as steroids, plasmapheresis, or intravenous immunoglobulin, may reduce the symptoms.





Anti-NMDA Receptor Encephalitis


Anti-NMDA receptor encephalitis, which results from antibodies directed against NMDA receptors, is a variety of paraneoplastic limbic encephalitis. It typically presents, like other forms of limbic encephalitis, with several days of progressively severe amnesia and behavioral disturbances. Then psychosis, seizures, involuntary movements, and autonomic instability often occur and eclipse the prodrome. This disorder typically occurs in young adults, especially young women. Neurologists might initially suspect – in decreasing order of probability – herpes simplex encephalitis, bacterial meningitis, phencyclidine (PCP) or other illicit drug intoxication, an anti-VGKC antibody paraneoplastic syndrome, and variant Creutzfeldt–Jakob – or an acute psychosis.


In most cases the MRI initially shows no abnormalities; however, the CSF shows a lymphocytic pleocytosis. The CSF and serum contain antibodies to NMDA receptors. The antibody concentration, greater in the serum than CSF, roughly correlates with the severity of the illness. The CSF also contains oligoclonal bands, as it does in the CSF of cases of multiple sclerosis and other CNS inflammatory illnesses.


The classic example of anti-NMDA receptor encephalitis consists of amnesia with mood change and depersonalization, involuntary movements, and eventually seizures in a young woman found to be harboring an ovarian teratoma. Overall, almost 50% of young adult women with this disorder harbor an ovarian teratoma, which presumably has triggered an antibody response to its neural tissue.



Lambert–Eaton Myasthenic Syndrome


In LEMS, small cell lung cancer provokes antibodies directed against the presynaptic side of the neuromuscular junction where they impair release of acetylcholine (ACh) (see Chapter 6). The antibody-induced neuromuscular junction dysfunction in LEMS causes proximal limb muscle weakness, which patients partly overcome with repetitive actions. Their weakness has different qualities and different distribution than myasthenia gravis – the well-known disorder of the ACh receptors on the postsynaptic side of the neuromuscular junction. Patients with myasthenia primarily have facial and extraocular muscle weakness that worsens on exertion. Antibody tests and electromyograms readily distinguish these two neuromuscular junction disorders.



Diagnostic Tests for Brain Tumors


Physicians should consider brain tumors and related conditions without waiting for a patient to have deficits. They should not rely exclusively on the mental status examination to distinguish between psychiatric disorders and brain tumors. In addition, commonplace complaints of fatigue, weight loss, menstrual irregularity, or infertility might prompt evaluation for pituitary insufficiency.


Neurologists generally order CT or MRI of the brain, admittedly liberally, for patients who have intellectual decline, those over 50 years who show substantial emotional changes, most adults with headaches not attributable to migraine, cluster, or giant cell arteritis (see Chapter 9), or, as previously discussed, those with excessive concern. Neurologists often also suggest CT or MRI for patients with any new psychiatric illness severe enough to warrant hospitalization or ECT.


CT remains a satisfactory screening procedure in many situations (see Chapter 20). It is sensitive to most tumors and other mass lesions, rapidly performed, relatively inexpensive, permissible for patients with pacemakers, and tolerable for most with claustrophobia. It remains preferable for detecting acute intracranial bleeding, including subarachnoid hemorrhage, subdural hematomas, and intracerebral hemorrhages. CT will also detect fractures and other abnormalities of the skull. On the other hand, its ionizing radiation, at least in children, carries a risk of inducing a malignancy (see Chapter 20).


MRI, especially with gadolinium infusion, remains superior in detecting lesions that are small or located in areas encased by bone, such as optic gliomas, acoustic neuromas, pituitary adenomas, and some posterior fossa tumors. It can readily demonstrate white-matter abnormalities associated with brain tumors, such as radiation necrosis, chemotherapy-induced leukoencephalopathy, and PML. If CT suggests a tumor, MRI still remains necessary to determine its exact location, internal structure, and involvement of surrounding brain. PET can help differentiate cerebral radiation necrosis from tumor recurrence.


For detecting tumors or other mass lesions, an EEG, especially in comparison to CT and MRI, is simply inappropriate. Nevertheless, in brain tumor and other cancer patients, it remains a good diagnostic test for delirium, particularly hepatic encephalopathy. An EEG may also assist in the diagnosis of seizures.


Neurologists generally do not perform an LP to analyze CSF when they suspect a brain tumor or other intracranial mass lesion because, in such cases, the CSF profile lacks a distinctive profile and rarely reveals malignant cells (see Chapter 20). More important, with large, expanding supratentorial mass lesions, an LP can precipitate transtentorial herniation (Fig. 19-3). Neurologists perform an LP when patients may have either carcinomatous or chronic infectious meningitis. Testing requires large volumes of CSF for neoplastic cells, chemistry studies, fungi, and bacterial and fungal antigens. In an exception to the general rule of not performing an LP in patients with a cerebral lesion, neurologists may perform one to test the CSF for Epstein–Barr virus in an AIDS patient found to have a cerebral tumor because a positive result would indicate a cerebral lymphoma and obviate surgery. Similarly, they may perform one in cases of suspected PML to look for JC virus DNA.


image

FIGURE 19-3 A patient in transtentorial herniation from a right-sided subdural hematoma (see Fig. 19-1, D) has coma, decerebrate (extensor) posture, Babinski signs, and a dilated right pupil. The right temporal lobe compressing the right-sided (ipsilateral) oculomotor nerve and brainstem through the tentorial notch causes this catastrophe.



Related Conditions



Pituitary Adenomas


Although clinicians often view pituitary adenomas as brain tumors, their symptoms, histology, and treatment differ considerably from those of glioblastomas, astrocytomas, and meningiomas. In classic studies, the usual manifestations of pituitary adenomas included profound mental, physical, and visual loss; however, those studies reported on patients whose symptoms resulted from large pituitary tumors that produced extraordinary levels of hormones, expanded out of the sella to encroach on the adjacent temporal lobes and optic chiasm, and obstructed the flow of CSF through the third ventricle. Physicians now routinely diagnose pituitary adenomas early in their course, while they remain microscopic in size, by using MRI and blood tests for hormone levels.


In both men and women, prolactinomas produce infertility, decreased libido, headache, and eventually characteristic visual field deficits. Additionally, in women, they produce amenorrhea and galactorrhea, and in men, erectile dysfunction and gynecomastia. Because their loss of libido encompasses the nonsexual as well as sexual aspects of their lives, patients with pituitary adenomas may appear depressed or cognitively impaired.


Most pituitary adenomas are either prolactinomas, which secrete prolactin, or chromophobe adenomas, which do not. Although prolactinomas usually remain microscopic, they sometimes grow larger than 10 mm, in which case neurologists consider them macroadenomas. Pituitary adenomas of that size may exert pressure on surrounding structures (Fig. 19-4). Their upward pressure on the diaphragm sellae usually causes bitemporal and generalized headache. Compressing the optic chiasm, which is above the diaphragm, causes the visual field deficits. Initially they cause bitemporal superior quadrantanopia and, with further enlargement, bitemporal hemianopsia (see Fig. 12-9).



MRI reveals almost all pituitary adenomas. Serum prolactin level determination usually shows elevations with prolactinomas and some chromophobe adenomas. Visual field testing helps detect those that have expanded out of the sella. Treatment varies with tumor type and size, presence of visual deficit, and institutional expertise, but the usual options include radiation, transsphenoidal microsurgery, and, with prolactin-secreting tumors, a dopamine agonist, such as bromocriptine or cabergoline. As in a previous caveat, treating large tumors with radiation or craniotomy risks causing panhypopituitarism and, from temporal lobe damage, memory impairment and seizures.


Less commonly occurring pituitary growths secrete growth hormone, which can cause acromegaly, or adrenocorticotropin hormone, which can lead to Cushing syndrome

Stay updated, free articles. Join our Telegram channel

Jun 4, 2016 | Posted by in NEUROLOGY | Comments Off on Brain Tumors, Metastatic Cancer, and Paraneoplastic Syndromes

Full access? Get Clinical Tree

Get Clinical Tree app for offline access